Case 4: Relapsed CLL/SLL with del(17p)/TP53 mutation and ibrutinib intolerance in a patient ≥65 years
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Case 3: Relapsed CLL/SLL without del(17p)/TP53 mutation in a patient ≥65 years
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Case 2: Newly Diagnosed CLL/SLL with del(17p)/TP53 mutation
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Case 1: Newly Diagnosed CLL/SLL without del(17p)/TP53 mutation in a patient <65 years without significant comorbidities
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Applying Guideline Updates and Real-World Experience in CLL: Experts Review State-of-the-Art Evidence and Address Clinical Challenges
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease
The therapeutic landscape of chronic lymphocytic leukemia (CLL) has evolved significantly in recent years, and the use of targeted therapy with small molecule inhibitors in the first-line setting will significantly alter the management of relapsed/refractory disease.
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use current/emerging therapeutic strategies in the care of their patients with CLL/SLL.

 

Pages

Subscribe to RSS - Chronic Lymphocytic Leukemia